Yes

Ophthalmic Agent, Mydriatic

Short-acting mydriatic used in diagnostic procedures; as well as preoperatively and postoperatively; treatment of some cases of acute iritis, iridocyclitis, and keratitis

C

Glaucoma, hypersensitivity to tropicamide or any component

Use with caution in infants and children since tropicamide may cause potentially dangerous CNS disturbances; tropicamide may cause an increase in intraocular pressure

1% to 10%:

Central nervous system: Parasympathetic stimulations, drowsiness, headache

Dermatologic: Eczematoid dermatitis

Gastrointestinal: Xerostomia

Local: Transient stinging

Ocular: Blurred vision, photophobia with or without corneal staining, increased intraocular pressure, follicular conjunctivitis

Symptoms of overdose include blurred vision, urinary retention, tachycardia, cardiorespiratory collapse

Antidote is physostigmine, pilocarpine; anticholinergic toxicity is caused by strong binding of the drug to cholinergic receptors. For anticholinergic overdose with severe life-threatening symptoms, physostigmine 1-2 mg (0.5 mg or 0.02 mg/kg for children) S.C. or I.V., slowly may be given to reverse systemic effects.

Store in tightly closed containers

Prevents the sphincter muscle of the iris and the muscle of the ciliary body from responding to cholinergic stimulation

Onset of mydriasis: ~20-40 minutes Duration: ~6-7 hours;

Onset of cycloplegia: Within 30 minutes; Duration: <6 hours

Children and Adults (individuals with heavily pigmented eyes may require larger doses):

Exam must be performed within 30 minutes after the repeat dose; if the patient is not examined within 20-30 minutes, instill an additional drop

Mydriasis: Instill 1-2 drops (0.5%) 15-20 minutes before exam; may repeat every 30 minutes as needed

Ophthalmic exam

May cause drowsiness

None reported

No information available to require special precautions

No effects or complications reported

If irritation persists or increases, discontinue use, may cause blurred vision and increased light sensitivity

Finger pressure should be applied on the lacrimal sac for 1-2 minutes following topical instillation of the solution

Solution, ophthalmic: 0.5% (2 mL, 15 mL); 1% (2 mL, 3 mL, 15 mL)

Caputo AR and Schnitzer RE, "Systemic Response to Mydriatic Eyedrops in Neonates: Mydriatics in Neonates," J Pediatr Ophthalmol Strabismus, 1978, 15(2):109-22.